ClinicalTrials.gg
CompletedNCT02527200Updated Jul 6, 2023Results posted

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

A Phase 3 interventional study of liraglutide and placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 32 sites in 8 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-07-06.

Primary conditionObesityRegistry: Nutrition DisordersReclassifiedWhy we changed it
Registry
Nutrition Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Nutrition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Enrollment
44th of 79
56 · median 70
Started
2015
with 3 others
Phase 3
17 of 79
1 open now
Registered
19th of 79
by date
Lead sponsor
16 of 79
Novo Nordisk A/S

Among the 79 studies testing liraglutide in Obesity, this one is the 44th largest by enrollment, is one of 4 that started in 2015, is one of 17 in phase 3, and was the 19th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.

03

Conditions studied

  • Metabolism and Nutrition Disorder
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 56 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Confirmed diagnosis of PWS (Prader-Willi Syndrome) (by genetic testing)
  • Male or female, age at the time of signing informed consent: - Part A: above or equal to 12 years and less than 18 years
  • Tanner stage 2-5 pubertal development for part A, and Tanner stage 1 for part B
  • (body mass index) corresponding to equal or above 30 kg/m\^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity)
  • Stable body weight during the previous 90 days before screening ( below 10 kg self-reported weight change)
  • Testing has been performed to evaluate for adrenal insufficiency and documented in medical record

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus (T1DM)
  • Type 2 diabetes mellitus (T2DM)
  • Calcitonin equal or above 50 ng/L
  • No change in treatment plan with growth hormone (GH) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off GH to stay off during this period. Adjustments in doses of growth hormone will be permitted)
  • Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroids Carcinoma (MTC)
  • History of pancreatitis (acute or chronic)
  • Treatment with any medication prescribed for weight loss within 90 days before screening (e.g. orlistat, zonisamide, topiramate/phentermine, lorcaserin, phentermine, bupropion/naltrexone,liraglutide, metformin)
  • Untreated adrenal insufficiency
  • Suggestive history of, or significant risk of gastroparesis (e.g. marked abdominal bloating post meal, history of vomiting, severe constipation), as judged by the Investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Liraglutide

    Drug: liraglutide

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

  • Drugplacebo

    Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

07

What researchers measure

Primary outcomes

  1. Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks

    Change in BMI SDS from baseline to week 16 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.

    Time frame: Week 0, Week 16

  2. Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks

    Change in BMI SDS from baseline to week 52 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.

    Time frame: Week 0, Week 52

Secondary outcomes

  1. Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16

    Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 16.

    Time frame: At week 16

  2. Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52

    Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 52.

    Time frame: At week 52

  3. Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16

    Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 16.

    Time frame: At week 16

  4. Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52

    Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 52.

    Time frame: At week 52

  5. Percentage of Participants With no Increase in BMI SDS at Week 16

    Percentage of participants with no increase in BMI SDS at week 16 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 16 and 'No' infers percentage of participants with increase in BMI SDS at week 16.

    Time frame: At week 16

  6. Percentage of Participants With no Increase in BMI SDS at Week 52

    Percentage of participants with no increase in BMI SDS at week 52 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 52 and 'No' infers percentage of participants with increase in BMI SDS at week 52.

    Time frame: At week 52

  7. Change in BMI From Baseline at Week 16

    Change in body mass index (BMI) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  8. Change in BMI From Baseline at Week 52

    Change in body mass index (BMI) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  9. Change in Body Weight (Kilogram (kg)) From Baseline at Week 16

    Change in body weight (kg) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  10. Change in Body Weight (kg) From Baseline at Week 52

    Change in body weight (kg) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  11. Change in Body Weight (Pounds (lb)) From Baseline at Week 16

    Change in body weight (lb) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  12. Change in Body Weight (lb) From Baseline at Week 52

    Change in body weight (lb) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  13. Change in Body Weight (Percentage [%]) From Baseline at Week 16

    Change in body weight (%) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  14. Change in Body Weight (%) From Baseline at Week 52

    Change in body weight (%) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  15. Change in Waist Circumference From Baseline at Week 16

    Change in waist circumference from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  16. Change in Waist Circumference From Baseline at Week 52

    Change in waist circumference from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  17. Change in Waist-to-hip Circumference Ratio From Baseline at Week 16

    Change in waist-to-hip circumference ratio from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  18. Change in Waist-to-hip Circumference Ratio From Baseline at Week 52

    Change in waist-to-hip circumference ratio from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  19. Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16

    Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 16 is presented. The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.

    Time frame: Week 0, week 16

  20. Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52

    Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 52 is presented.The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.

    Time frame: Week 0, week 52

  21. Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16

    Change in hsCRP from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  22. Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52

    Change in hsCRP from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  23. Change in Total Cholesterol From Baseline at Week 16

    Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  24. Change in Total Cholesterol From Baseline at Week 52

    Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  25. Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16

    Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  26. Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52

    Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  27. Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16

    Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  28. Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52

    Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  29. Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16

    Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  30. Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52

    Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  31. Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16

    Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  32. Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52

    Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  33. Change in Triglycerides From Baseline at Week 16

    Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  34. Change in Triglycerides From Baseline at Week 52

    Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  35. Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16

    Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  36. Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52

    Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  37. Change in Systolic and Diastolic Blood Pressure From Baseline at Week 16

    Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  38. Change in Systolic and Diastolic Blood Pressure From Baseline at Week 52

    Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  39. Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16

    Change in HbA1c from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  40. Change in HbA1c From Baseline at Week 52

    Change in HbA1c from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  41. Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16

    Change in FPG from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  42. Change in FPG From Baseline at Week 52

    Change in FPG from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  43. Change in Fasting Insulin From Baseline at Week 16

    Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  44. Change in Fasting Insulin From Baseline at Week 52

    Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  45. Change in Fasting C Peptide From Baseline at Week 16

    Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.

    Time frame: Week 0, week 16

  46. Change in Fasting C Peptide From Baseline at Week 52

    Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.

    Time frame: Week 0, week 52

  47. Number of Participants in Glycaemic Category at Week 16

    Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 16 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.

    Time frame: week 16

  48. Number of Participants in Glycaemic Category at Week 52

    Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.

    Time frame: Week 52

  49. Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16

    Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).

    Time frame: Week 0, week 16

  50. Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52

    Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).

    Time frame: Week 0, week 52

  51. Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16

    Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.

    Time frame: Week 0, week 16

  52. Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52

    Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.

    Time frame: Week 0, week 52

  53. Number of Treatment Emergent Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period. On-treatment period included AEs are with an onset date on or after the first day of trial product administration and any of the following dates, whichever came first: a) 14 days after the last day on trial product, or b) Follow-up visit (week 54) for participants with trial product discontinuation, or c) Last study visit (participants withdrawn without follow-up visit (week 54)).

    Time frame: From week 0 to week 54

  54. Number of Severe Treatment Emergent Episodes of Hypoglycaemia

    Hypoglycaemic episode (blood glucose less than or equal to (\<=) 3.9 mmol/L (70 mg/dL) Or greater than (\>) 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia defined by American Diabetes Association (ADA) 2013 and International Society for Paediatric and Adolescent Diabetes (ISPAD) 2018: hypoglycaemic episode associated with severe cognitive impairment requiring external assistance for recovery. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).

    Time frame: From week 0 to week 54

  55. Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia

    Symptomatic blood glucose confirmed hypoglycaemia: An episode that is blood glucose confirmed by plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episode is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).

    Time frame: From week 0 to week 54

  56. Number of Participants With Occurrence of Anti-liraglutide Antibodies

    Number of participants with occurrence of anti-liraglutide antibodies is presented. In the below table, 'Yes' infers number of participants with occurrence of anti- liraglutide antibodies and 'No' infers number of participants without anti- liraglutide antibodies.

    Time frame: From week 0 to week 54

  57. Number of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16

    A 12-lead ECG was performed at baseline (week 0) and week 16 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and weeks 16 are presented.

    Time frame: Week 0, Week 16

  58. Number of Participants With Change in ECG From Baseline at Week 52

    A 12-lead ECG was performed at baseline (week 0) and week 52 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and week 52 are presented.

    Time frame: Week 0, Week 52

  59. Change in Pulse From Baseline at Week 16

    Change in pulse from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  60. Change in Pulse From Baseline at Week 52

    Change in pulse from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  61. Change in Haematology: Haemoglobin From Baseline at Week 16

    Change in haemoglobin from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  62. Change in Haematology: Haemoglobin From Baseline at Week 52

    Change in haemoglobin from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  63. Change in Haematology: Haematocrit From Baseline at Week 16

    Change in haematocrit from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  64. Change in Haematology: Haematocrit From Baseline at Week 52

    Change in haematocrit from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  65. Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16

    Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  66. Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52

    Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  67. Change in Haematology: Erythrocytes From Baseline at Week 16

    Change in erythrocytes from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  68. Change in Haematology: Erythrocytes From Baseline at Week 52

    Change in erythrocytes from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  69. Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16

    Change in creatinine and bilirubin (total) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  70. Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52

    Change in creatinine and bilirubin (total) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  71. Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16

    Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  72. Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52

    Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  73. Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16

    Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  74. Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52

    Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  75. Change in Biochemistry: Albumin From Baseline at Week 16

    Change in albumin from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  76. Change in Biochemistry: Albumin From Baseline at Week 52

    Change in albumin from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  77. Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16

    Change in CEA serum from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  78. Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52

    Change in CEA serum from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  79. Change in Hormone Level: Calcitonin From Baseline at Week 16

    Change in calcitonin from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  80. Change in Hormone Level: Calcitonin From Baseline at Week 52

    Change in calcitonin from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  81. Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16

    Change in TSH and prolactin from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  82. Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52

    Change in TSH and prolactin from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  83. Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16

    Change in free T4 and ACTH from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  84. Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52

    Change in free T4 and ACTH from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  85. Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16

    Change in IGF-1 and cortisol from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  86. Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52

    Change in IGF-1 and cortisol from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  87. Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16

    Change in DHEAS from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  88. Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52

    Change in DHEAS from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  89. Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16

    Change in LH and FSH from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  90. Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52

    Change in LH and FSH from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  91. Change in Hormone Level: Estradiol (Females) From Baseline at Week 16

    Change in estradiol (only for females) from baseline to week 16 is presented.

    Time frame: Week 0, week 16

  92. Change in Hormone Level: Estradiol (Females) From Baseline at Week 52

    Change in estradiol (only for females) from baseline to week 52 is presented.

    Time frame: Week 0, week 52

  93. Change in Hormone Level: Testosterone (Males) From Baseline at Week 16

    Change in testosterone (only for males) from baseline to week 16 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.

    Time frame: Week 0, week 16

  94. Change in Hormone Level: Testosterone (Males) From Baseline at Week 52

    Change in testosterone (only for males) from baseline to week 52 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.

    Time frame: Week 0, week 52

  95. Number of Participants With Change in Pubertal Status From Baseline at Week 16

    This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0), week 16. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".

    Time frame: Week 0, week 16

  96. Number of Participants With Change in Pubertal Status From Baseline at Week 52

    This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0) and week 52. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".

    Time frame: Week 0, week 52

  97. Number of Participants With Change in Physical Examination From Baseline at Week 16

    This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 16. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.

    Time frame: Week 0, week 16

  98. Number of Participants With Change in Physical Examination From Baseline at Week 52

    This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.

    Time frame: Week 0, week 52

  99. Height Velocity at Week 16

    Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Weeks 16 is presented.

    Time frame: Week 16

  100. Height Velocity at Week 52

    Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Week 52 are presented.

    Time frame: week 52

  101. Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16

    C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 16. The questionnaire was not used in Part B due to the young age of the participants in Part B.

    Time frame: Week 0, week 16

  102. Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52

    C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.

    Time frame: Week 0, week 52

  103. Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16

    Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 16. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.

    Time frame: Week 0, week 16

  104. Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52

    Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.

    Time frame: Week 0, week 52

08

Results

Posted Feb 3, 2022

Participant flow

The trial was conducted at 20 sites in 8 countries as follows: Australia (2), Canada (1), France (7), Italy (2), Netherlands (1), New Zealand (1), Turkey (3), and the United States (3).

Participant flow — Overall Study
MilestonePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: Placebo
Started2012177
Safety analysis set (sas)2012177
Full analysis set (fas)1912177
Completed179157
Not completed3320
Withdrew: Withdrawal by subject3210
Withdrew: Unclassified0100
Withdrew: Lost to follow-up0010

Outcome measures

PrimaryChange in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks

Change in BMI SDS from baseline to week 16 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.

Time frame:
Week 0, Week 16
Reported as:
Mean · SDS score
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks
SDS scorePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks-0.18 ± 0.21-0.18 ± 0.23-0.50 ± 0.65-0.48 ± 0.39-0.33 ± 0.49-0.29 ± 0.32
PrimaryChange in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks

Change in BMI SDS from baseline to week 52 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.

Time frame:
Week 0, Week 52
Reported as:
Mean · SDS score
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks
SDS scorePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks-0.27 ± 0.37-0.13 ± 0.25-0.79 ± 1.21-0.71 ± 0.68-0.50 ± 0.88-0.36 ± 0.53
SecondaryPercentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16

Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 16.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16
Percentage of participantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Yes27.88.337.557.132.426.3
No72.291.762.542.967.673.7
SecondaryPercentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52

Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 52.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52
Percentage of participantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Yes29.418.235.742.932.327.8
No70.681.864.357.167.772.2
SecondaryPercentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16

Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 16.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16
Percentage of participantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Yes006.314.32.95.3
No10010093.885.797.194.7
SecondaryPercentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52

Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 52.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52
Percentage of participantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Yes11.8014.328.612.911.1
No88.210085.771.487.188.9
SecondaryPercentage of Participants With no Increase in BMI SDS at Week 16

Percentage of participants with no increase in BMI SDS at week 16 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 16 and 'No' infers percentage of participants with increase in BMI SDS at week 16.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With no Increase in BMI SDS at Week 16
Percentage of participantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Yes66.775.087.510076.584.2
No33.325.012.5023.515.8
SecondaryPercentage of Participants With no Increase in BMI SDS at Week 52

Percentage of participants with no increase in BMI SDS at week 52 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 52 and 'No' infers percentage of participants with increase in BMI SDS at week 52.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With no Increase in BMI SDS at Week 52
Percentage of participantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Yes70.672.778.610073.381.3
No29.427.321.4026.718.8
SecondaryChange in BMI From Baseline at Week 16

Change in body mass index (BMI) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · kilogram per meter square (kg/m^2)
Change in BMI From Baseline at Week 16
kilogram per meter square (kg/m^2)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in BMI From Baseline at Week 16-0.9 ± 1.4-0.8 ± 1.6-1.1 ± 1.5-1.5 ± 1.7-1.0 ± 1.4-1.1 ± 1.6
SecondaryChange in BMI From Baseline at Week 52

Change in body mass index (BMI) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · kg/m^2
Change in BMI From Baseline at Week 52
kg/m^2Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in BMI From Baseline at Week 520.8 ± 2.2-0.1 ± 2.1-0.6 ± 3.3-0.7 ± 2.7-0.7 ± 2.7-0.4 ± 2.3
SecondaryChange in Body Weight (Kilogram (kg)) From Baseline at Week 16

Change in body weight (kg) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · (kilogram (kg))
Change in Body Weight (Kilogram (kg)) From Baseline at Week 16
(kilogram (kg))Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Weight (Kilogram (kg)) From Baseline at Week 16-1.7 ± 3.6-1.1 ± 5.0-0.6 ± 2.2-1.0 ± 2.7-1.2 ± 3.0-1.0 ± 4.2
SecondaryChange in Body Weight (kg) From Baseline at Week 52

Change in body weight (kg) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · kilogram
Change in Body Weight (kg) From Baseline at Week 52
kilogramPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Weight (kg) From Baseline at Week 52-0.4 ± 6.31.9 ± 6.03.0 ± 6.62.8 ± 5.21.1 ± 6.52.3 ± 5.6
SecondaryChange in Body Weight (Pounds (lb)) From Baseline at Week 16

Change in body weight (lb) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · pounds (lb)
Change in Body Weight (Pounds (lb)) From Baseline at Week 16
pounds (lb)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Weight (Pounds (lb)) From Baseline at Week 16-3.7 ± 7.8-2.4 ± 11.0-1.4 ± 4.8-2.1 ± 5.9-2.6 ± 6.6-2.3 ± 9.2
SecondaryChange in Body Weight (lb) From Baseline at Week 52

Change in body weight (lb) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · pounds
Change in Body Weight (lb) From Baseline at Week 52
poundsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Weight (lb) From Baseline at Week 52-0.9 ± 13.94.3 ± 13.26.7 ± 14.46.2 ± 11.52.5 ± 14.45.0 ± 12.3
SecondaryChange in Body Weight (Percentage [%]) From Baseline at Week 16

Change in body weight (%) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Percent change in body weight
Change in Body Weight (Percentage [%]) From Baseline at Week 16
Percent change in body weightPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Weight (Percentage [%]) From Baseline at Week 16-1.7 ± 3.8-0.7 ± 3.7-1.1 ± 4.1-2.2 ± 5.5-1.4 ± 3.9-1.2 ± 4.3
SecondaryChange in Body Weight (%) From Baseline at Week 52

Change in body weight (%) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · Percent change in body weight
Change in Body Weight (%) From Baseline at Week 52
Percent change in body weightPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Body Weight (%) From Baseline at Week 52-0.4 ± 6.52.3 ± 5.76.3 ± 12.14.9 ± 8.62.6 ± 9.93.3 ± 6.9
SecondaryChange in Waist Circumference From Baseline at Week 16

Change in waist circumference from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · centimeters (cm)
Change in Waist Circumference From Baseline at Week 16
centimeters (cm)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Waist Circumference From Baseline at Week 16-2.50 ± 4.52-2.44 ± 7.84-0.73 ± 6.14-1.04 ± 4.53-1.70 ± 5.31-1.92 ± 6.70
SecondaryChange in Waist Circumference From Baseline at Week 52

Change in waist circumference from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · centimeter
Change in Waist Circumference From Baseline at Week 52
centimeterPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Waist Circumference From Baseline at Week 52-2.98 ± 8.68-3.48 ± 7.320.45 ± 8.050.97 ± 5.99-1.49 ± 8.45-2.09 ± 7.06
SecondaryChange in Waist-to-hip Circumference Ratio From Baseline at Week 16

Change in waist-to-hip circumference ratio from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Waist-to-hip circumference ratio
Change in Waist-to-hip Circumference Ratio From Baseline at Week 16
Waist-to-hip circumference ratioPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Waist-to-hip Circumference Ratio From Baseline at Week 16-0.01 ± 0.04-0.02 ± 0.060.00 ± 0.060.01 ± 0.04-0.01 ± 0.05-0.01 ± 0.05
SecondaryChange in Waist-to-hip Circumference Ratio From Baseline at Week 52

Change in waist-to-hip circumference ratio from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · waist-to-hip circumference ratio
Change in Waist-to-hip Circumference Ratio From Baseline at Week 52
waist-to-hip circumference ratioPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Waist-to-hip Circumference Ratio From Baseline at Week 52-0.01 ± 0.06-0.04 ± 0.06-0.02 ± 0.05-0.01 ± 0.07-0.02 ± 0.06-0.03 ± 0.06
SecondaryChange in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16

Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 16 is presented. The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.

Time frame:
Week 0, week 16
Reported as:
Mean · Score on a scale
Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16
Score on a scalePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Hyperphagia behaviour score-0.8 ± 2.01-1.7 ± 4.14-1.2 ± 3.83-2.6 ± 2.07-1.0 ± 2.97-2.0 ± 3.48
Hyperphagia drive score-0.9 ± 2.80-0.9 ± 2.61-1.8 ± 2.97-2.0 ± 2.89-1.3 ± 2.87-1.3 ± 2.69
Hyperphagia severity score-0.6 ± 1.54-0.3 ± 2.46-0.1 ± 1.650.1 ± 1.46-0.4 ± 1.59-0.2 ± 2.12
Hyperphagia total score-2.4 ± 5.55-2.9 ± 5.79-3.1 ± 7.28-4.4 ± 5.65-2.7 ± 6.34-3.5 ± 5.63
SecondaryChange in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52

Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 52 is presented.The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.

Time frame:
Week 0, week 52
Reported as:
Mean · Score on a scale
Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52
Score on a scalePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Hyperphagia behaviour score-0.9 ± 3.20-0.6 ± 2.62-0.7 ± 4.63-2.6 ± 3.65-0.8 ± 3.82-1.3 ± 3.00
Hyperphagia drive score-2.2 ± 2.90-0.5 ± 2.42-1.1 ± 3.99-1.4 ± 4.45-1.7 ± 3.41-0.8 ± 3.06
Hyperphagia severity score-1.3 ± 1.81-0.9 ± 2.51-0.4 ± 2.73-1.4 ± 1.82-0.9 ± 2.27-1.1 ± 2.26
Hyperphagia total score-4.4 ± 6.57-2.1 ± 6.11-2.1 ± 10.11-5.4 ± 8.32-3.4 ± 8.23-3.1 ± 6.77
SecondaryChange in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16

Change in hsCRP from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Milligram per liter (mg/L)
Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16
Milligram per liter (mg/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 160.79 ± 2.58-0.57 ± 6.61-2.79 ± 8.031.87 ± 2.12-0.61 ± 5.570.24 ± 5.57
SecondaryChange in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52

Change in hsCRP from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · mg/L
Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52
mg/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 520.25 ± 2.550.14 ± 3.67-2.42 ± 9.19-0.37 ± 0.84-0.89 ± 6.31-0.03 ± 2.99
SecondaryChange in Total Cholesterol From Baseline at Week 16

Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of total cholesterol
Change in Total Cholesterol From Baseline at Week 16
Ratio of total cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Total Cholesterol From Baseline at Week 160.99 ± 0.101.06 ± 0.141.02 ± 0.110.97 ± 0.101.00 ± 0.101.03 ± 0.14
SecondaryChange in Total Cholesterol From Baseline at Week 52

Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of total cholesterol
Change in Total Cholesterol From Baseline at Week 52
Ratio of total cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Total Cholesterol From Baseline at Week 521.00 ± 0.181.06 ± 0.151.01 ± 0.121.07 ± 0.071.01 ± 0.151.06 ± 0.13
SecondaryChange in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16

Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of LDL-cholesterol
Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16
Ratio of LDL-cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 161.01 ± 0.151.13 ± 0.191.04 ± 0.170.96 ± 0.141.02 ± 0.161.07 ± 0.19
SecondaryChange in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52

Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of LDL-cholesterol
Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52
Ratio of LDL-cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 521.02 ± 0.221.12 ± 0.230.99 ± 0.191.06 ± 0.101.01 ± 0.201.10 ± 0.19
SecondaryChange in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16

Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of HDL-cholesterol
Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16
Ratio of HDL-cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 160.96 ± 0.141.00 ± 0.201.01 ± 0.141.12 ± 0.130.98 ± 0.141.04 ± 0.19
SecondaryChange in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52

Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of HDL-cholesterol
Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52
Ratio of HDL-cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 520.99 ± 0.191.02 ± 0.171.06 ± 0.161.08 ± 0.121.02 ± 0.181.04 ± 0.15
SecondaryChange in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16

Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of non-HDL cholesterol
Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16
Ratio of non-HDL cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 161.02 ± 0.161.09 ± 0.151.03 ± 0.160.93 ± 0.121.02 ± 0.151.04 ± 0.16
SecondaryChange in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52

Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of non-HDL cholesterol
Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52
Ratio of non-HDL cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 521.02 ± 0.221.07 ± 0.191.00 ± 0.161.07 ± 0.131.01 ± 0.191.07 ± 0.17
SecondaryChange in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16

Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of VLDL cholesterol
Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16
Ratio of VLDL cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 161.05 ± 0.360.98 ± 0.271.05 ± 0.460.80 ± 0.171.05 ± 0.400.93 ± 0.25
SecondaryChange in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52

Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of VLDL cholesterol
Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52
Ratio of VLDL cholesterolPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 521.06 ± 0.350.95 ± 0.361.03 ± 0.261.13 ± 0.311.04 ± 0.311.01 ± 0.34
SecondaryChange in Triglycerides From Baseline at Week 16

Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of triglycerides
Change in Triglycerides From Baseline at Week 16
Ratio of triglyceridesPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Triglycerides From Baseline at Week 161.04 ± 0.360.99 ± 0.261.05 ± 0.440.80 ± 0.181.05 ± 0.390.93 ± 0.25
SecondaryChange in Triglycerides From Baseline at Week 52

Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of triglycerides
Change in Triglycerides From Baseline at Week 52
Ratio of triglyceridesPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Triglycerides From Baseline at Week 521.07 ± 0.360.94 ± 0.361.04 ± 0.291.12 ± 0.321.06 ± 0.321.00 ± 0.35
SecondaryChange in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16

Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of FFA
Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16
Ratio of FFAPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 161.52 ± 1.601.31 ± 0.611.04 ± 0.350.99 ± 0.301.31 ± 1.211.21 ± 0.55
SecondaryChange in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52

Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of FFA
Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52
Ratio of FFAPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 521.15 ± 0.761.45 ± 0.490.85 ± 0.511.05 ± 0.251.01 ± 0.671.32 ± 0.45
SecondaryChange in Systolic and Diastolic Blood Pressure From Baseline at Week 16

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Systolic and Diastolic Blood Pressure From Baseline at Week 16
Millimeters of mercury (mmHg)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
SBP: Change from week 0 to week 16-5 ± 15-2 ± 132 ± 92 ± 6-1 ± 13-1 ± 11
DBP: Change from week 0 to week 16-1 ± 100 ± 71 ± 8-1 ± 170 ± 90 ± 11
SecondaryChange in Systolic and Diastolic Blood Pressure From Baseline at Week 52

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Systolic and Diastolic Blood Pressure From Baseline at Week 52
Millimeters of mercury (mmHg)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
SBP: Change from week 0 to week 52-5 ± 64 ± 124 ± 157 ± 8-1 ± 115 ± 11
DBP: Change from week 0 to week 52-3 ± 95 ± 134 ± 131 ± 70 ± 114 ± 12
SecondaryChange in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16

Change in HbA1c from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Percentage point of HbA1c
Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16
Percentage point of HbA1cPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16-0.2 ± 0.10 ± 0.3-0.2 ± 0.3-0.2 ± 0.3-0.2 ± 0.2-0.1 ± 0.3
SecondaryChange in HbA1c From Baseline at Week 52

Change in HbA1c from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · Percentage point of HbA1c
Change in HbA1c From Baseline at Week 52
Percentage point of HbA1cPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in HbA1c From Baseline at Week 52-0.2 ± 0.20.1 ± 0.3-0.2 ± 0.4-0.1 ± 0.3-0.2 ± 0.30.1 ± 0.3
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline at Week 16

Change in FPG from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16
mmol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16-0.2 ± 0.50.1 ± 0.5-0.1 ± 0.50.2 ± 0.4-0.2 ± 0.50.1 ± 0.4
SecondaryChange in FPG From Baseline at Week 52

Change in FPG from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in FPG From Baseline at Week 52
mmol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in FPG From Baseline at Week 520 ± 0.70.3 ± 0.80 ± 0.40 ± 0.40 ± 0.60.2 ± 0.7
SecondaryChange in Fasting Insulin From Baseline at Week 16

Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of fasting insulin
Change in Fasting Insulin From Baseline at Week 16
Ratio of fasting insulinPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Fasting Insulin From Baseline at Week 161.59 ± 1.910.78 ± 0.321.43 ± 1.171.32 ± 0.681.52 ± 1.620.97 ± 0.53
SecondaryChange in Fasting Insulin From Baseline at Week 52

Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of fasting insulin
Change in Fasting Insulin From Baseline at Week 52
Ratio of fasting insulinPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Fasting Insulin From Baseline at Week 522.03 ± 2.330.79 ± 0.371.45 ± 1.271.22 ± 0.441.78 ± 1.940.96 ± 0.44
SecondaryChange in Fasting C Peptide From Baseline at Week 16

Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of fasting C peptide
Change in Fasting C Peptide From Baseline at Week 16
Ratio of fasting C peptidePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Fasting C Peptide From Baseline at Week 161.14 ± 0.560.86 ± 0.201.11 ± 0.501.08 ± 0.441.13 ± 0.530.94 ± 0.31
SecondaryChange in Fasting C Peptide From Baseline at Week 52

Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of fasting C peptide
Change in Fasting C Peptide From Baseline at Week 52
Ratio of fasting C peptidePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Fasting C Peptide From Baseline at Week 521.34 ± 0.920.91 ± 0.231.15 ± 0.451.09 ± 0.301.26 ± 0.750.98 ± 0.26
SecondaryNumber of Participants in Glycaemic Category at Week 16

Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 16 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.

Time frame:
week 16
Reported as:
Count of participants · Participants
Number of Participants in Glycaemic Category at Week 16
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Normoglycaemia1681152713
Pre-diabetes242246
Type 2 diabetes000000
SecondaryNumber of Participants in Glycaemic Category at Week 52

Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants in Glycaemic Category at Week 52
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Normoglycaemia134102236
Pre-diabetes242347
Type 2 diabetes110011
SecondaryChange in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16

Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of HOMA-B
Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16
Ratio of HOMA-BPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 161.69 ± 1.930.70 ± 0.311.55 ± 1.041.07 ± 0.511.63 ± 1.590.82 ± 0.41
SecondaryChange in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52

Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of HOMA-B
Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52
Ratio of HOMA-BPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 522.24 ± 1.850.65 ± 0.301.50 ± 1.501.25 ± 0.501.91 ± 1.710.88 ± 0.48
SecondaryChange in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16

Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.

Time frame:
Week 0, week 16
Reported as:
Mean · Ratio of HOMA-IR
Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16
Ratio of HOMA-IRPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 161.57 ± 1.920.80 ± 0.351.43 ± 1.261.33 ± 0.821.51 ± 1.650.97 ± 0.58
SecondaryChange in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52

Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.

Time frame:
Week 0, week 52
Reported as:
Mean · Ratio of HOMA-IR
Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52
Ratio of HOMA-IRPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 522.26 ± 3.130.88 ± 0.501.45 ± 1.231.24 ± 0.481.90 ± 2.461.02 ± 0.51
SecondaryNumber of Treatment Emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period. On-treatment period included AEs are with an onset date on or after the first day of trial product administration and any of the following dates, whichever came first: a) 14 days after the last day on trial product, or b) Follow-up visit (week 54) for participants with trial product discontinuation, or c) Last study visit (participants withdrawn without follow-up visit (week 54)).

Time frame:
From week 0 to week 54
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events
EventsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Number of Treatment Emergent Adverse Events13437159829345
SecondaryNumber of Severe Treatment Emergent Episodes of Hypoglycaemia

Hypoglycaemic episode (blood glucose less than or equal to (\<=) 3.9 mmol/L (70 mg/dL) Or greater than (\>) 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia defined by American Diabetes Association (ADA) 2013 and International Society for Paediatric and Adolescent Diabetes (ISPAD) 2018: hypoglycaemic episode associated with severe cognitive impairment requiring external assistance for recovery. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).

Time frame:
From week 0 to week 54
Reported as:
Number · Episodes
Number of Severe Treatment Emergent Episodes of Hypoglycaemia
EpisodesPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Number of Severe Treatment Emergent Episodes of Hypoglycaemia001010
SecondaryNumber of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia

Symptomatic blood glucose confirmed hypoglycaemia: An episode that is blood glucose confirmed by plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episode is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).

Time frame:
From week 0 to week 54
Reported as:
Number · Episodes
Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia
EpisodesPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia000000
SecondaryNumber of Participants With Occurrence of Anti-liraglutide Antibodies

Number of participants with occurrence of anti-liraglutide antibodies is presented. In the below table, 'Yes' infers number of participants with occurrence of anti- liraglutide antibodies and 'No' infers number of participants without anti- liraglutide antibodies.

Time frame:
From week 0 to week 54
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Anti-liraglutide Antibodies
ParticipantsPart A: LiraglutidePart B: LiraglutidePart A+B: Liraglutide
Yes213
No14822
SecondaryNumber of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16

A 12-lead ECG was performed at baseline (week 0) and week 16 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and weeks 16 are presented.

Time frame:
Week 0, Week 16
Reported as:
Count of participants · Participants
Number of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Week 0: Normal20121763718
Week 0: Abnormal, NCS000101
Week 0: Abnormal, CS000000
Week 16: Normal17121373019
Week 16: Abnormal, NCS001010
Week 16: Abnormal, CS000000
SecondaryNumber of Participants With Change in ECG From Baseline at Week 52

A 12-lead ECG was performed at baseline (week 0) and week 52 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and week 52 are presented.

Time frame:
Week 0, Week 52
Reported as:
Count of participants · Participants
Number of Participants With Change in ECG From Baseline at Week 52
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Week 0: Normal20121763718
Week 0: Abnormal, NCS000101
Week 0: Abnormal, CS000000
Week 52: Normal1791343013
Week 52: Abnormal, NCS110011
Week 52: Abnormal, CS000000
SecondaryChange in Pulse From Baseline at Week 16

Change in pulse from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Beats/minute
Change in Pulse From Baseline at Week 16
Beats/minutePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Pulse From Baseline at Week 162 ± 12-2 ± 51 ± 16-9 ± 102 ± 14-4 ± 8
SecondaryChange in Pulse From Baseline at Week 52

Change in pulse from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · Beats/minute
Change in Pulse From Baseline at Week 52
Beats/minutePart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Pulse From Baseline at Week 521 ± 13-8 ± 1010 ± 11-6 ± 85 ± 13-7 ± 10
SecondaryChange in Haematology: Haemoglobin From Baseline at Week 16

Change in haemoglobin from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · millimoles per liter (mmol/L)
Change in Haematology: Haemoglobin From Baseline at Week 16
millimoles per liter (mmol/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Haematology: Haemoglobin From Baseline at Week 16-0.18 ± 0.430.06 ± 0.28-0.20 ± 1.22-0.07 ± 0.55-0.19 ± 0.840.01 ± 0.38
SecondaryChange in Haematology: Haemoglobin From Baseline at Week 52

Change in haemoglobin from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in Haematology: Haemoglobin From Baseline at Week 52
mmol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Haematology: Haemoglobin From Baseline at Week 52-0.14 ± 0.79-0.01 ± 0.31-0.02 ± 0.61-0.02 ± 0.20-0.09 ± 0.72-0.01 ± 0.28
SecondaryChange in Haematology: Haematocrit From Baseline at Week 16

Change in haematocrit from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Percentage of haematocrit in blood
Change in Haematology: Haematocrit From Baseline at Week 16
Percentage of haematocrit in bloodPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Haematology: Haematocrit From Baseline at Week 16-1.8 ± 2.1-0.5 ± 1.30.4 ± 2.6-0.6 ± 3.3-0.9 ± 2.6-0.5 ± 2.1
SecondaryChange in Haematology: Haematocrit From Baseline at Week 52

Change in haematocrit from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · Percentage of haematocrit in blood
Change in Haematology: Haematocrit From Baseline at Week 52
Percentage of haematocrit in bloodPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Haematology: Haematocrit From Baseline at Week 52-1.4 ± 4.00 ± 1.7-0.2 ± 2.7-0.8 ± 2.6-0.9 ± 3.5-0.3 ± 1.9
SecondaryChange in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16

Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · 10^9 cells per liter (10^9/L)
Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16
10^9 cells per liter (10^9/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Thrombocytes: Change from week 0 to week 166 ± 35-21 ± 268 ± 6619 ± 187 ± 49-8 ± 30
Leukocytes: Change from week 0 to week 16-0.1 ± 1.5-0.3 ± 1.6-0.8 ± 2.3-1.1 ± 1.7-0.4 ± 1.9-0.6 ± 1.6
Eosinophils: Change from week 0 to week 16-0.03 ± 0.090.04 ± 0.07-0.14 ± 0.270.07 ± 0.32-0.07 ± 0.200.05 ± 0.19
Neutrophils: Change from week 0 to week 160.11 ± 1.08-0.22 ± 1.62-0.28 ± 1.59-1.35 ± 1.33-0.06 ± 1.31-0.62 ± 1.58
Basophils: Change from week 0 to week 16-0.01 ± 0.020 ± 0.02-0.01 ± 0.04-0.01 ± 0.04-0.01 ± 0.030 ± 0.03
Lymphocytes: Change from week 0 to week 16-0.24 ± 0.66-0.09 ± 0.97-0.36 ± 0.890.09 ± 0.85-0.29 ± 0.76-0.02 ± 0.91
Monocytes: Change from week 0 to week 160.06 ± 0.17-0.04 ± 0.12-0.05 ± 0.170.05 ± 0.200.01 ± 0.18-0.01 ± 0.15
SecondaryChange in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52

Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · 10^9 cells per liter (10^9/L)
Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52
10^9 cells per liter (10^9/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Thrombocytes: Change from week 0 to week 5218 ± 44-7 ± 39-2 ± 3737 ± 7010 ± 425 ± 49
Leukocytes: Change from week 0 to week 52-0.2 ± 1.1-0.6 ± 1.7-0.7 ± 2.80.3 ± 3.0-0.4 ± 1.9-0.3 ± 2.1
Eosinophils: Change from week 0 to week 520.01 ± 0.110.03 ± 0.19-0.13 ± 0.36-0.17 ± 0.13-0.05 ± 0.24-0.03 ± 0.20
Neutrophils: Change from week 0 to week 520.11 ± 1.17-0.76 ± 1.40-0.03 ± 2.03-0.07 ± 2.550.05 ± 1.53-0.55 ± 1.75
Basophils: Change from week 0 to week 520 ± 0.030 ± 0.04-0.01 ± 0.040.02 ± 0.04-0.01 ± 0.040.01 ± 0.04
Lymphocytes: Change from week 0 to week 52-0.28 ± 0.670.19 ± 0.70-0.47 ± 0.590.39 ± 0.49-0.36 ± 0.630.25 ± 0.63
Monocytes: Change from week 0 to week 52-0.04 ± 0.19-0.06 ± 0.22-0.05 ± 0.190.14 ± 0.20-0.04 ± 0.190 ± 0.23
SecondaryChange in Haematology: Erythrocytes From Baseline at Week 16

Change in erythrocytes from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · 10^12 cells per liter (10^12/L)
Change in Haematology: Erythrocytes From Baseline at Week 16
10^12 cells per liter (10^12/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Haematology: Erythrocytes From Baseline at Week 16-0.1 ± 0.20 ± 0.20.1 ± 0.30 ± 0.3-0.1 ± 0.30 ± 0.2
SecondaryChange in Haematology: Erythrocytes From Baseline at Week 52

Change in erythrocytes from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · 10^12 cells per liter (10^12/L)
Change in Haematology: Erythrocytes From Baseline at Week 52
10^12 cells per liter (10^12/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Haematology: Erythrocytes From Baseline at Week 52-0.1 ± 0.40 ± 0.2-0.1 ± 0.30 ± 0-0.1 ± 0.40 ± 0.1
SecondaryChange in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16

Change in creatinine and bilirubin (total) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · micro mole per liter (umol/L)
Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16
micro mole per liter (umol/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Creatinine: Change from week 0 to week 161 ± 50 ± 62 ± 70 ± 61 ± 50 ± 6
Bilirubin (total): Change from week 0 to week 160 ± 20 ± 20 ± 21 ± 20 ± 20 ± 2
SecondaryChange in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52

Change in creatinine and bilirubin (total) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · umol/L
Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52
umol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Creatinine: Change from week 0 to week 523 ± 8-4 ± 93 ± 65 ± 33 ± 7-1 ± 9
Bilirubin (total): Change from week 0 to week 520 ± 22 ± 30 ± 12 ± 30 ± 22 ± 3
SecondaryChange in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16

Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Units per liter (U/L)
Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16
Units per liter (U/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Creatinine kinase: Change from week 0 to week 16-3 ± 3716 ± 453 ± 23-5 ± 5-1 ± 3210 ± 39
Amylase: Change from week 0 to week 165 ± 13-2 ± 58 ± 128 ± 86 ± 131 ± 8
Lipase: Change from week 0 to week 1610 ± 60 ± 48 ± 71 ± 29 ± 60 ± 3
ALT: Change from week 0 to week 16-9 ± 32-4 ± 18-2 ± 6-25 ± 23-6 ± 25-10 ± 21
AST: Change from week 0 to week 16-6 ± 140 ± 10-2 ± 5-18 ± 24-4 ± 11-6 ± 17
ALP: Change from week 0 to week 16-10 ± 12-7 ± 25-21 ± 36-47 ± 42-14 ± 24-19 ± 35
SecondaryChange in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52

Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · Units per liter (U/L)
Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52
Units per liter (U/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Creatinine kinase: Change from week 0 to week 5230 ± 206-4 ± 2925 ± 42-8 ± 2528 ± 159-5 ± 27
Amylase: Change from week 0 to week 524 ± 102 ± 127 ± 128 ± 55 ± 114 ± 11
Lipase: Change from week 0 to week 529 ± 9-1 ± 37 ± 63 ± 58 ± 80 ± 4
ALT: Change from week 0 to week 521 ± 124 ± 250 ± 16-24 ± 281 ± 14-6 ± 29
AST: Change from week 0 to week 52-2 ± 79 ± 311 ± 7-21 ± 32-1 ± 70 ± 33
ALP: Change from week 0 to week 52-24 ± 27-35 ± 27-25 ± 59-26 ± 60-24 ± 42-32 ± 39
SecondaryChange in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16

Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · mmol/L
Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16
mmol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Urea: Change from week 0 to week 160.03 ± 1.45-0.51 ± 0.670 ± 0.990.09 ± 2.190.02 ± 1.26-0.31 ± 1.33
Sodium: Change from week 0 to week 160 ± 52 ± 31 ± 40 ± 10 ± 41 ± 3
Potassium: Change from week 0 to week 160.1 ± 0.4-0.1 ± 0.3-0.2 ± 0.6-0.1 ± 0.20 ± 0.5-0.1 ± 0.2
Calcium: Change from week 0 to week 160 ± 0.120 ± 0.100.08 ± 0.170.02 ± 0.100.03 ± 0.140.01 ± 0.10
SecondaryChange in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52

Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52
mmol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Urea: Change from week 0 to week 52-0.38 ± 1.56-0.34 ± 0.54-0.21 ± 1.00-0.04 ± 1.08-0.31 ± 1.34-0.24 ± 0.74
Sodium: Change from week 0 to week 52-1 ± 5-2 ± 51 ± 42 ± 20 ± 4-1 ± 4
Potassium: Change from week 0 to week 52-0.2 ± 0.6-0.1 ± 0.2-0.2 ± 0.70 ± 0.2-0.2 ± 0.6-0.1 ± 0.2
Calcium: Change from week 0 to week 52-0.05 ± 0.14-0.11 ± 0.120.09 ± 0.140 ± 0.020.01 ± 0.15-0.08 ± 0.11
SecondaryChange in Biochemistry: Albumin From Baseline at Week 16

Change in albumin from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · gram per deciliter (g/dL)
Change in Biochemistry: Albumin From Baseline at Week 16
gram per deciliter (g/dL)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Biochemistry: Albumin From Baseline at Week 160 ± 0.20 ± 0.10 ± 0.20 ± 0.10 ± 0.20 ± 0.1
SecondaryChange in Biochemistry: Albumin From Baseline at Week 52

Change in albumin from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · g/dL
Change in Biochemistry: Albumin From Baseline at Week 52
g/dLPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Biochemistry: Albumin From Baseline at Week 52-0.1 ± 0.7-0.1 ± 0.30 ± 0.20 ± 0.10 ± 0.5-0.1 ± 0.2
SecondaryChange in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16

Change in CEA serum from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · nanogram per milliliter (ng/mL)
Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16
nanogram per milliliter (ng/mL)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16-0.01 ± 0.11-0.17 ± 0.300.17 ± 0.55-0.04 ± 0.100.07 ± 0.38-0.12 ± 0.24
SecondaryChange in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52

Change in CEA serum from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · ng/mL
Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52
ng/mLPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 520.03 ± 0.38-0.14 ± 0.26-0.01 ± 0.140.17 ± 0.240.01 ± 0.29-0.01 ± 0.29
SecondaryChange in Hormone Level: Calcitonin From Baseline at Week 16

Change in calcitonin from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · nanogram per liter (ng/L)
Change in Hormone Level: Calcitonin From Baseline at Week 16
nanogram per liter (ng/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Calcitonin From Baseline at Week 160 ± 00 ± 00.3 ± 1.10 ± 00.1 ± 0.70 ± 0
SecondaryChange in Hormone Level: Calcitonin From Baseline at Week 52

Change in calcitonin from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · ng/L
Change in Hormone Level: Calcitonin From Baseline at Week 52
ng/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Calcitonin From Baseline at Week 520.1 ± 0.60 ± 00.5 ± 1.20 ± 00.3 ± 0.90 ± 0
SecondaryChange in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16

Change in TSH and prolactin from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · Milli-international units/liter (mIU/L)
Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16
Milli-international units/liter (mIU/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
TSH: Change from week 0 to week 16-0.34 ± 0.68-0.01 ± 0.72-0.09 ± 1.13-0.59 ± 0.67-0.23 ± 0.89-0.23 ± 0.74
Prolactin: Change from week 0 to week 167 ± 27-6 ± 330 ± 13-22 ± 634 ± 22-12 ± 45
SecondaryChange in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52

Change in TSH and prolactin from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · mIU/L
Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52
mIU/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
TSH: Change from week 0 to week 520.02 ± 1.59-0.48 ± 0.63-0.75 ± 2.13-0.17 ± 1.08-0.30 ± 1.83-0.38 ± 0.78
Prolactin: Change from week 0 to week 5210 ± 388 ± 37-3 ± 3729 ± 335 ± 3715 ± 36
SecondaryChange in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16

Change in free T4 and ACTH from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · picomole per liter (pmol/L)
Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16
picomole per liter (pmol/L)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
T4: Change from week 0 to week 16-0.6 ± 1.40.3 ± 1.10.7 ± 2.30.1 ± 1.7-0.1 ± 1.90.2 ± 1.3
ACTH: Change from week 0 to week 160.99 ± 5.22-0.85 ± 2.22-0.37 ± 1.49-1.32 ± 1.870.42 ± 4.10-1.02 ± 2.04
SecondaryChange in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52

Change in free T4 and ACTH from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · pmol/L
Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52
pmol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
T4: Change from week 0 to week 52-0.4 ± 1.71.9 ± 2.7-0.1 ± 2.00.8 ± 2.3-0.3 ± 1.81.5 ± 2.5
ACTH: Change from week 0 to week 52-0.02 ± 2.021.29 ± 3.500.98 ± 5.640.20 ± 2.410.42 ± 3.990.89 ± 3.07
SecondaryChange in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16

Change in IGF-1 and cortisol from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · nanogram per milliliter (ng/mL)
Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16
nanogram per milliliter (ng/mL)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
IGF-1: Change from week 0 to week 16-56.89 ± 126.46-28.23 ± 95.792.41 ± 84.98-14.23 ± 75.01-30.31 ± 112.09-23.86 ± 87.54
Cortisol: Change from week 0 to week 16-22.94 ± 41.366.75 ± 38.72-8.09 ± 22.98-23.08 ± 59.02-16.71 ± 35.16-4.85 ± 48.33
SecondaryChange in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52

Change in IGF-1 and cortisol from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · ng/mL
Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52
ng/mLPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
IGF-1: Change from week 0 to week 52-25.90 ± 195.61-103.45 ± 136.61-1.47 ± 112.9310.40 ± 56.69-15.04 ± 161.72-59.66 ± 123.62
Cortisol: Change from week 0 to week 523.60 ± 50.637.54 ± 33.71-14.15 ± 43.8421.67 ± 46.62-4.01 ± 47.8212.59 ± 37.65
SecondaryChange in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16

Change in DHEAS from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · umol/L
Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16
umol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 160.16 ± 1.740.21 ± 0.950.25 ± 1.101.00 ± 1.420.20 ± 1.480.46 ± 1.13
SecondaryChange in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52

Change in DHEAS from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · umol/L
Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52
umol/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 520.77 ± 1.180.76 ± 0.970.25 ± 0.660.74 ± 1.260.55 ± 1.010.76 ± 1.01
SecondaryChange in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16

Change in LH and FSH from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · IU/L
Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16
IU/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
LH: Change from week 0 to week 16-0.04 ± 1.280.06 ± 0.74-0.07 ± 0.250.22 ± 0.42-0.05 ± 0.970.12 ± 0.63
FSH: Change from week 0 to week 16-0.2 ± 2.50.2 ± 1.0-0.1 ± 1.31.0 ± 1.1-0.2 ± 2.10.5 ± 1.1
SecondaryChange in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52

Change in LH and FSH from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · IU/L
Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52
IU/LPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
LH: Change from week 0 to week 520.16 ± 2.330.06 ± 0.790.37 ± 0.960.30 ± 0.510.24 ± 1.870.14 ± 0.70
FSH: Change from week 0 to week 521.1 ± 3.90.4 ± 1.60.4 ± 1.80.7 ± 1.60.8 ± 3.10.6 ± 1.5
SecondaryChange in Hormone Level: Estradiol (Females) From Baseline at Week 16

Change in estradiol (only for females) from baseline to week 16 is presented.

Time frame:
Week 0, week 16
Reported as:
Mean · picograms per milliliter (pg/mL)
Change in Hormone Level: Estradiol (Females) From Baseline at Week 16
picograms per milliliter (pg/mL)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Estradiol (Females) From Baseline at Week 160.9 ± 15.89.2 ± 11.91.6 ± 3.80 ± 01.2 ± 12.26.1 ± 10.4
SecondaryChange in Hormone Level: Estradiol (Females) From Baseline at Week 52

Change in estradiol (only for females) from baseline to week 52 is presented.

Time frame:
Week 0, week 52
Reported as:
Mean · pg/mL
Change in Hormone Level: Estradiol (Females) From Baseline at Week 52
pg/mLPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Change in Hormone Level: Estradiol (Females) From Baseline at Week 527.0 ± 32.613.7 ± 21.61.6 ± 4.50 ± NA4.1 ± 21.811.0 ± 19.7
SecondaryChange in Hormone Level: Testosterone (Males) From Baseline at Week 16

Change in testosterone (only for males) from baseline to week 16 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.

Time frame:
Week 0, week 16
Reported as:
Mean · nanomoles per liter (nmol/L)
Change in Hormone Level: Testosterone (Males) From Baseline at Week 16
nanomoles per liter (nmol/L)Part A: LiraglutidePart A: Placebo
Change in Hormone Level: Testosterone (Males) From Baseline at Week 161.55 ± 2.010.61 ± 1.66
SecondaryChange in Hormone Level: Testosterone (Males) From Baseline at Week 52

Change in testosterone (only for males) from baseline to week 52 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.

Time frame:
Week 0, week 52
Reported as:
Mean · nmol/L
Change in Hormone Level: Testosterone (Males) From Baseline at Week 52
nmol/LPart A: LiraglutidePart A: Placebo
Change in Hormone Level: Testosterone (Males) From Baseline at Week 520.62 ± 1.40-0.34 ± 1.51
SecondaryNumber of Participants With Change in Pubertal Status From Baseline at Week 16

This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0), week 16. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".

Time frame:
Week 0, week 16
Reported as:
Count of participants · Participants
Number of Participants With Change in Pubertal Status From Baseline at Week 16
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Week 0: Breast development (for female) — Stage 100112112
Week 0: Breast development (for female) — Stage 2100010
Week 0: Breast development (for female) — Stage 3820082
Week 0: Breast development (for female) — Stage 4010001
Week 0: Breast development (for female) — Stage 5220022
Week 16: Breast development (for female) — Stage 1006262
Week 16: Breast development (for female) — Stage 2103040
Week 16: Breast development (for female) — Stage 3710071
Week 16: Breast development (for female) — Stage 4020002
Week 16: Breast development (for female) — Stage 5220022
Week 0: Pubic hair development (for female) — Stage 1106171
Week 0: Pubic hair development (for female) — Stage 2203050
Week 0: Pubic hair development (for female) — Stage 3320133
Week 0: Pubic hair development (for female) — Stage 4312051
Week 0: Pubic hair development (for female) — Stage 5220022
Week 16: Pubic hair development (for female) — Stage 1103141
Week 16: Pubic hair development (for female) — Stage 2105060
Week 16: Pubic hair development (for female) — Stage 3410142
Week 16: Pubic hair development (for female) — Stage 4221032
Week 16: Pubic hair development (for female) — Stage 5220022
Week 0: Pubic hair development (for male) — Stage 1006363
Week 0: Pubic hair development (for male) — Stage 2300131
Week 0: Pubic hair development (for male) — Stage 3240125
Week 0: Pubic hair development (for male) — Stage 4220022
Week 0: Pubic hair development (for male) — Stage 5210021
Week 16: Pubic hair development (for male) — Stage 1006161
Week 16: Pubic hair development (for male) — Stage 2200323
Week 16: Pubic hair development (for male) — Stage 3230124
Week 16: Pubic hair development (for male) — Stage 4220022
Week 16: Pubic hair development (for male) — Stage 5320032
Week 0: Penis development (for male) — Stage 1016566
Week 0: Penis development (for male) — Stage 2430043
Week 0: Penis development (for male) — Stage 3110011
Week 0: Penis development (for male) — Stage 4320032
Week 0: Penis development (for male) — Stage 5100010
Week 16: Penis development (for male) — Stage 1015556
Week 16: Penis development (for male) — Stage 2211031
Week 16: Penis development (for male) — Stage 3230023
Week 16: Penis development (for male) — Stage 4210021
Week 16: Penis development (for male) — Stage 5310031
SecondaryNumber of Participants With Change in Pubertal Status From Baseline at Week 52

This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0) and week 52. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".

Time frame:
Week 0, week 52
Reported as:
Count of participants · Participants
Number of Participants With Change in Pubertal Status From Baseline at Week 52
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Week 0: Breast development (for female) — Stage 100112112
Week 0: Breast development (for female) — Stage 2100010
Week 0: Breast development (for female) — Stage 3820082
Week 0: Breast development (for female) — Stage 4010001
Week 0: Breast development (for female) — Stage 5220022
Week 52: Breast development (for female) — Stage 1002121
Week 52: Breast development (for female) — Stage 2004040
Week 52: Breast development (for female) — Stage 3512071
Week 52: Breast development (for female) — Stage 4120012
Week 52: Breast development (for female) — Stage 5320032
Week 0: Pubic hair development (for female) — Stage 1106171
Week 0: Pubic hair development (for female) — Stage 2203050
Week 0: Pubic hair development (for female) — Stage 3320133
Week 0: Pubic hair development (for female) — Stage 4312051
Week 0: Pubic hair development (for female) — Stage 5220022
Week 52: Pubic hair development (for female) — Stage 1101020
Week 52: Pubic hair development (for female) — Stage 2102030
Week 52: Pubic hair development (for female) — Stage 3214162
Week 52: Pubic hair development (for female) — Stage 4321042
Week 52: Pubic hair development (for female) — Stage 5220022
Week 0: Pubic hair development (for male) — Stage 1006363
Week 0: Pubic hair development (for male) — Stage 2300131
Week 0: Pubic hair development (for male) — Stage 3240125
Week 0: Pubic hair development (for male) — Stage 4220022
Week 0: Pubic hair development (for male) — Stage 5210021
Week 52: Pubic hair development (for male) — Stage 1004040
Week 52: Pubic hair development (for male) — Stage 2001111
Week 52: Pubic hair development (for male) — Stage 3320133
Week 52: Pubic hair development (for male) — Stage 4330134
Week 52: Pubic hair development (for male) — Stage 5310031
Week 0: Penis development (for male) — Stage 1016566
Week 0: Penis development (for male) — Stage 2430043
Week 0: Penis development (for male) — Stage 3110011
Week 0: Penis development (for male) — Stage 4320032
Week 0: Penis development (for male) — Stage 5100010
Week 52: Penis development (for male) — Stage 1013233
Week 52: Penis development (for male) — Stage 2112132
Week 52: Penis development (for male) — Stage 3210021
Week 52: Penis development (for male) — Stage 4320032
Week 52: Penis development (for male) — Stage 5310031
SecondaryNumber of Participants With Change in Physical Examination From Baseline at Week 16

This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 16. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.

Time frame:
Week 0, week 16
Reported as:
Count of participants · Participants
Number of Participants With Change in Physical Examination From Baseline at Week 16
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
General Appearance: Week 0 — Normal14101252615
General Appearance: Week 0 — Abnormal, NCS213152
General Appearance: Week 0 — Abnormal, CS412162
General Appearance: Week 16 — Normal14111152516
General Appearance: Week 16 — Abnormal, NCS104151
General Appearance: Week 16 — Abnormal, CS410142
Head, ears, eyes, nose, throat, neck: Week 0 — Normal19101563416
Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, NCS122133
Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, CS000000
Head, ears, eyes, nose, throat, neck: Week 16 — Normal18121573319
Head, ears, eyes, nose, throat, neck: Week 16 — Abnormal, NCS100010
Head, ears, eyes, nose, throat, neck: Week 16 — Abnormal, CS000000
Respiratory system: Week 0 — Normal20121673619
Respiratory system: Week 0 — Abnormal, NCS001010
Respiratory system: Week 0 — Abnormal, CS000000
Respiratory system: Week 16 — Normal19121573419
Respiratory system: Week 16 — Abnormal, NCS000000
Respiratory system: Week 16 — Abnormal, CS000000
Cardiovascular system: Week 0 — Normal19121773619
Cardiovascular system: Week 0 — Abnormal, NCS100010
Cardiovascular system: Week 0 — Abnormal, CS000000
Cardiovascular system: Week 16 — Normal18121573319
Cardiovascular system: Week 16 — Abnormal, NCS100010
Cardiovascular system: Week 16 — Abnormal, CS000000
GI system including mouth: Week 0 — Normal19121773619
GI system including mouth: Week 0 — Abnormal, NCS100010
GI system including mouth: Week 0 — Abnormal, CS000000
GI system including mouth: Week 16 — Normal17121573219
GI system including mouth: Week 16 — Abnormal, NCS200020
GI system including mouth: Week 16 — Abnormal, CS000000
Musculoskeletal system: Week 0 — Normal1591462915
Musculoskeletal system: Week 0 — Abnormal, NCS323163
Musculoskeletal system: Week 0 — Abnormal, CS210021
Musculoskeletal system: Week 16 — Normal1691162715
Musculoskeletal system: Week 16 — Abnormal, NCS214162
Musculoskeletal system: Week 16 — Abnormal, CS120012
CNS and PNS: Week 0 — Normal16101563116
CNS and PNS: Week 0 — Abnormal, NCS201131
CNS and PNS: Week 0 — Abnormal, CS221032
CNS and PNS: Week 16 — Normal15111472918
CNS and PNS: Week 16 — Abnormal, NCS201030
CNS and PNS: Week 16 — Abnormal, CS210021
Skin: Week 0 — Normal1171062113
Skin: Week 0 — Abnormal, NCS6461125
Skin: Week 0 — Abnormal, CS311041
Skin: Week 16 — Normal1281062214
Skin: Week 16 — Abnormal, NCS5350103
Skin: Week 16 — Abnormal, CS210122
Thyroid gland: Week 0 — Normal20121773719
Thyroid gland: Week 0 — Abnormal, NCS000000
Thyroid gland: Week 0 — Abnormal, CS000000
Thyroid gland: Week 16 — Normal19121573419
Thyroid gland: Week 16 — Abnormal, NCS000000
Thyroid gland: Week 16 — Abnormal, CS000000
Lymph node palpation: Week 0 — Normal19121773619
Lymph node palpation: Week 0 — Abnormal, NCS100010
Lymph node palpation: Week 0 — Abnormal, CS000000
Lymph node palpation: Week 16 — Normal19121573419
Lymph node palpation: Week 16 — Abnormal, NCS000000
Lymph node palpation: Week 16 — Abnormal, CS000000
SecondaryNumber of Participants With Change in Physical Examination From Baseline at Week 52

This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.

Time frame:
Week 0, week 52
Reported as:
Count of participants · Participants
Number of Participants With Change in Physical Examination From Baseline at Week 52
ParticipantsPart A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
General Appearance: Week 0 — Normal14101252615
General Appearance: Week 0 — Abnormal, NCS213152
General Appearance: Week 0 — Abnormal, CS412162
General Appearance: Week 52 — Normal1310952215
General Appearance: Week 52 — Abnormal, NCS102030
General Appearance: Week 52 — Abnormal, CS311041
Head, ears, eyes, nose, throat, neck: Week 0 — Normal19101563416
Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, NCS122133
Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, CS000000
Head, ears, eyes, nose, throat, neck: Week 52 — Normal15111242715
Head, ears, eyes, nose, throat, neck: Week 52 — Abnormal, NCS200121
Head, ears, eyes, nose, throat, neck: Week 52 — Abnormal, CS000000
Respiratory system: Week 0 — Normal20121673619
Respiratory system: Week 0 — Abnormal, NCS001010
Respiratory system: Week 0 — Abnormal, CS000000
Cardiovascular system: Week 0 — Normal19121773619
Cardiovascular system: Week 0 — Abnormal, NCS100010
Cardiovascular system: Week 0 — Abnormal, CS000000
Cardiovascular system: Week 52 — Normal17101252915
Cardiovascular system: Week 52 — Abnormal, NCS000000
Cardiovascular system: Week 52 — Abnormal, CS010001
GI system including mouth: Week 0 — Normal19121773619
GI system including mouth: Week 0 — Abnormal, NCS100010
GI system including mouth: Week 0 — Abnormal, CS000000
GI system including mouth: Week 52 — Normal16111252816
GI system including mouth: Week 52 — Abnormal, NCS100010
GI system including mouth: Week 52 — Abnormal, CS000000
Musculoskeletal system: Week 0 — Normal1591462915
Musculoskeletal system: Week 0 — Abnormal, NCS323163
Musculoskeletal system: Week 0 — Abnormal, CS210021
Musculoskeletal system: Week 52 — Normal15101052515
Musculoskeletal system: Week 52 — Abnormal, NCS112031
Musculoskeletal system: Week 52 — Abnormal, CS100010
CNS and PNS: Week 0 — Normal16101563116
CNS and PNS: Week 0 — Abnormal, NCS201131
CNS and PNS: Week 0 — Abnormal, CS221032
CNS and PNS: Week 52 — Normal13101142414
CNS and PNS: Week 52 — Abnormal, NCS100111
CNS and PNS: Week 52 — Abnormal, CS211031
Skin: Week 0 — Normal1171062113
Skin: Week 0 — Abnormal, NCS6461125
Skin: Week 0 — Abnormal, CS311041
Skin: Week 52 — Normal138942212
Skin: Week 52 — Abnormal, NCS323062
Skin: Week 52 — Abnormal, CS110112
Thyroid gland: Week 0 — Normal20121773719
Thyroid gland: Week 0 — Abnormal, NCS000000
Thyroid gland: Week 0 — Abnormal, CS000000
Thyroid gland: Week 52 — Normal17111252916
Thyroid gland: Week 52 — Abnormal, NCS000000
Thyroid gland: Week 52 — Abnormal, CS000000
Lymph node palpation: Week 0 — Normal19121773619
Lymph node palpation: Week 0 — Abnormal, NCS100010
Lymph node palpation: Week 0 — Abnormal, CS000000
Lymph node palpation: Week 52 — Normal17111252916
Lymph node palpation: Week 52 — Abnormal, NCS000000
Lymph node palpation: Week 52 — Abnormal, CS000000
SecondaryHeight Velocity at Week 16

Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Weeks 16 is presented.

Time frame:
Week 16
Reported as:
Mean · Centimeters/year (cm/yr)
Height Velocity at Week 16
Centimeters/year (cm/yr)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Height Velocity at Week 162.113 ± 3.0842.718 ± 4.2814.190 ± 2.6046.898 ± 2.8863.090 ± 3.0144.258 ± 4.274
SecondaryHeight Velocity at Week 52

Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Week 52 are presented.

Time frame:
week 52
Reported as:
Mean · Centimeters/year (cm/yr)
Height Velocity at Week 52
Centimeters/year (cm/yr)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboPart A+B: LiraglutidePart A+B: Placebo
Height Velocity at Week 521.564 ± 1.2851.839 ± 1.6584.752 ± 2.2505.620 ± 1.6903.004 ± 2.3833.173 ± 2.466
SecondaryPart A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16

C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 16. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Time frame:
Week 0, week 16
Reported as:
Count of participants · Participants
Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16
ParticipantsPart A: LiraglutidePart A: Placebo
Week 0: Suicidal ideation13
Week 0: Suicidal behaviour00
Week 16: Suicidal ideation11
Week 16: Suicidal behaviour00
SecondaryPart A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52

C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Time frame:
Week 0, week 52
Reported as:
Count of participants · Participants
Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52
ParticipantsPart A: LiraglutidePart A: Placebo
Week 0: Suicidal ideation13
Week 0: Suicidal behaviour00
Week 52: Suicidal ideation10
Week 52: Suicidal behaviour00
SecondaryPart A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16

Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 16. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Time frame:
Week 0, week 16
Reported as:
Mean · Score on a scale
Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16
Score on a scalePart A: LiraglutidePart A: Placebo
Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16-2 ± 41 ± 5
SecondaryPart A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52

Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Time frame:
Week 0, week 52
Reported as:
Mean · Score on a scale
Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52
Score on a scalePart A: LiraglutidePart A: Placebo
Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52-2 ± 30 ± 3

Adverse events

Collected over From week 0 to week 54 Results are based on SAS which included all participants exposed to at least one dose of trial product. All AEs reported here are TEAEs. TEAE is as an event that had onset date during on-treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Liraglutide0/20 (0%)1/20 (5%)16/20 (80%)
Part B: Liraglutide0/17 (0%)2/17 (11.8%)17/17 (100%)
Part A: Placebo0/12 (0%)0/12 (0%)10/12 (83.3%)
Part B: Placebo0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Most frequent serious events
Most frequent serious events
EventPart A: LiraglutidePart B: LiraglutidePart A: PlaceboPart B: Placebo
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/200/170/121/7
ArthrodesisSurgical and medical procedures0/201/170/120/7
HyperthermiaGeneral disorders0/201/170/120/7
Spinal operationSurgical and medical procedures0/201/170/120/7
Staphylococcal infectionInfections and infestations0/201/170/120/7
CholelithiasisHepatobiliary disorders1/200/170/120/7
Most frequent other events
Showing 10 of 109
Most frequent other events
EventPart A: LiraglutidePart B: LiraglutidePart A: PlaceboPart B: Placebo
DiarrhoeaGastrointestinal disorders10/207/172/120/7
Abdominal painGastrointestinal disorders6/203/173/120/7
InfluenzaInfections and infestations2/202/171/122/7
HeadacheNervous system disorders2/202/173/120/7
Abdominal pain upperGastrointestinal disorders1/203/170/120/7
VomitingGastrointestinal disorders2/203/170/120/7
MalaiseGeneral disorders1/200/172/120/7
ConstipationGastrointestinal disorders3/200/170/120/7
NasopharyngitisInfections and infestations3/202/171/120/7
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/202/170/121/7

Baseline characteristics

Full analysis set (FAS) which included all randomised participants who received at least one dose of trial product and had any post-randomisation data.

Age, Customized
Age, Customized(Participants)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboTotal
6 - <12 years0017724
12 - <18 years19120031
Sex: Female, Male
Sex: Female, Male(Participants)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboTotal
Female10511228
Male976527
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboTotal
Hispanic or Latino10315
Not Hispanic or Latino181211647
Unknown or Not Reported00303
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: LiraglutidePart A: PlaceboPart B: LiraglutidePart B: PlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00101
Black or African American20103
White11610734
More than one race00000
Unknown or Not Reported665017
09

Study locations

32 sites
  • Novo Nordisk Investigational Site
    Santa Monica, California 90404, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21229, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14203, United States
  • Novo Nordisk Investigational Site
    Mineola, New York 11501, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43235, United States
  • Novo Nordisk Investigational Site
    Camperdown, New South Wales 2050, Australia
  • Novo Nordisk Investigational Site
    Parkville, Victoria 3052, Australia
  • Novo Nordisk Investigational Site
    Calgary, Alberta T3B 6A8, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • Novo Nordisk Investigational Site
    ANGERS cedex 09, 49033, France
  • Novo Nordisk Investigational Site
    Bordeaux, 33076, France
  • Novo Nordisk Investigational Site
    Brest, 29609, France
  • Novo Nordisk Investigational Site
    BRON cedex, 69677, France
  • Novo Nordisk Investigational Site
    Haguenau, 67504, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    MARSEILLE Cédex 05, 13385, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 05, 34295, France
  • Novo Nordisk Investigational Site
    Nice, 06200, France
  • Novo Nordisk Investigational Site
    Paris, 75012, France
  • Novo Nordisk Investigational Site
    Paris, 75015, France
  • Novo Nordisk Investigational Site
    Rouen, 76031, France
  • Novo Nordisk Investigational Site
    Toulouse cedex 9, 31059, France
  • Novo Nordisk Investigational Site
    Fiumicino, 00050, Italy
  • Novo Nordisk Investigational Site
    Milano, 20132, Italy
  • Novo Nordisk Investigational Site
    Padova, 35128, Italy
  • Novo Nordisk Investigational Site
    Rotterdam, 3015 CN, Netherlands
  • Novo Nordisk Investigational Site
    Grafton, 1023, New Zealand
  • Novo Nordisk Investigational Site
    Ankara, 06010, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34093, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34890, Turkey
  • Novo Nordisk Investigational Site
    Samsun, 55139, Turkey
  • Novo Nordisk Investigational Site
    Trabzon, 61080, Turkey
10

References and documents

Publications

  • Diene G, Angulo M, Hale PM, Jepsen CH, Hofman PL, Hokken-Koelega A, Ramesh C, Turan S, Tauber M. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. J Clin Endocrinol Metab. 2022 Dec 17;108(1):4-12. doi: 10.1210/clinem/dgac549. PubMed 36181471 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Nov 2020, 59 months.

Results were first posted in Feb 2022, 1 year 2 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 59 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2015
First posted
Aug 18, 2015
StartActual
Nov 9, 2015
Primary completionActual
Nov 4, 2020
CompletionActual
Nov 19, 2020
Results first posted
Feb 3, 2022
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02527200
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 18, 2015
Start date
Nov 9, 2015
Primary completion
Nov 4, 2020
Completion
Nov 19, 2020
Results posted
Feb 3, 2022
Last update
Jul 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion